NL-OMON27120尚未招募不适用
Pancreatic Cancer Surveillance in CDKN2A and Other High Risk Mutation Carriers
eiden University Medical Center0 个研究点目标入组 280 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 280
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Participating in the PC surveillance program, which requires:
- •A proven CDKN2A or LKB1/STK11 mutation and = 40 years old
- •A proven BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, or MSH6 mutation with at least one affected first degree blood relative with pancreatic cancer and = 45 years old.
- •Screening for all mutation carriers ends at the age of 75 years.
排除标准
- •Comorbidity leading to an impaired physical performance (World health organization (WHO) performance status 3-4) or mental retardation
- •Life expectancy < 5 years.
- •Very limited understanding of the Dutch or English language to be able to make an informed choice.
- •No informed consent.
研究者
相似试验
已完成
不适用
Pancreatic cancer surveillance in CDKN2A and other high risk mutation carriers'p16-Leiden'pancreatic malignancy1002766410017991NL-OMON50801eids Universitair Medisch Centrum280
已完成
不适用
Tumor profiling in pancreatic carcinoma, a multidisciplinary initiativepancreatic carcinoma10017990pancreatic cancerNL-OMON35953Academisch Medisch Centrum200
进行中（未招募）
不适用
Screening newly diagnosed diabetics for pancreatic cancer using a blood and urine testPancreatic cancer, diabetesMalignant neoplasm of pancreas, diabetes mellitusCancerISRCTN85533678Spital Freiburg1,000
招募中
不适用
Koasato university Pancreatic cancer Screening Projectpancreatic cancerJPRN-UMIN000046880Kitasato University Hospital2,500
已完成
不适用
Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic TumorsPancreatic TumorNCT01692873Institut Paoli-Calmettes274